ViewRay, Inc. (NASDAQ:VRAY) major shareholder International Ltd Fosun sold 4,300,000 shares of the firm’s stock in a transaction on Tuesday, June 8th. The shares were sold at an average price of $5.97, for a total transaction of $25,671,000.00. Following the completion of the transaction, the insider now directly owns 2,813,834 shares of the company’s stock, valued at approximately $16,798,588.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.
Shares of NASDAQ:VRAY opened at $5.76 on Friday. ViewRay, Inc. has a 52-week low of $1.88 and a 52-week high of $7.36. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.13 and a quick ratio of 4.24. The firm has a market cap of $931.62 million, a P/E ratio of -8.00 and a beta of 1.05. The firm has a 50-day moving average price of $5.12.
ViewRay (NASDAQ:VRAY) last released its quarterly earnings data on Thursday, May 6th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01). ViewRay had a negative net margin of 183.76% and a negative return on equity of 69.14%. Equities research analysts anticipate that ViewRay, Inc. will post -0.68 earnings per share for the current year.
Several equities analysts have recently weighed in on VRAY shares. Guggenheim upgraded ViewRay from a “neutral” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Friday, May 7th. BTIG Research raised ViewRay from a “neutral” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Friday, March 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $4.86.
ViewRay, Inc designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment.
Featured Article: Diluted Earnings Per Share
Receive News & Ratings for ViewRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ViewRay and related companies with MarketBeat.com's FREE daily email newsletter.